Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 325 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Active Clear all
Not listed No phase listed Observational

Impact of Physical Activity and Diet on Symptom Experience in People Living With HIV

NCT03790501
View directory record Official record
Conditions
HIV/AIDS
Interventions
No intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 27, 2026, 12:33 AM EDT
Terminated Not applicable Interventional

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

NCT00203853
View directory record Official record
Conditions
HIV Infections
Interventions
pillbox, wristwatch
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1 Interventional

A Study of PMPA in HIV-Infected Patients

NCT00002180
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

NCT00031343
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2007 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

NCT00594880
View directory record Official record
Conditions
HIV Infections
Interventions
Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

NCT00766597
View directory record Official record
Conditions
HIV Infections
Interventions
Vicriviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 27, 2026, 12:33 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
4,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 12:33 AM EDT
Completed No phase listed Observational

A Study of Anal Cancer Development in HIV Infected People

NCT00107679
View directory record Official record
Conditions
HIV Infections, Anus Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 27, 2026, 12:33 AM EDT
Not listed Phase 1 Interventional

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

NCT00002396
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 12:33 AM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00002451
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Miami, Florida • Albany, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1 Interventional

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

NCT00002183
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 27, 2026, 12:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Defining Sexual Activity

NCT02085746
View directory record Official record
Conditions
Demographics Effecting One's Definition of Being Sexually Active
Interventions
Defining Sexual Activity Questionnaire
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
10
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

NCT01631201
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
Rifalazil 25 milligram, Azithromycin 1 gram
Drug
Lead sponsor
ActivBiotics Pharma, LLC
Industry
Eligibility
19 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 27, 2026, 12:33 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

NCT00089583
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
LEXIVA (GW433908), Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Not applicable Interventional Results available

The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men

NCT03839212
View directory record Official record
Conditions
Human Immunodeficiency Virus, Cardiometabolic Risk
Interventions
HOLA Component 1, HOLA Component 2, HOLA Component 3, HOLA Component 4
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

NCT04212091
View directory record Official record
Conditions
HIV Infections
Interventions
PGT121.414.LS, VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

NCT04021290
View directory record Official record
Conditions
HIV Infections
Interventions
DTG/3TC FDC, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 27, 2026, 12:33 AM EDT
Completed Not applicable Interventional Results available

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NCT00491556
View directory record Official record
Conditions
HIV Infections
Interventions
Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 27, 2026, 12:33 AM EDT